ISDA: 4DWK

Deposition Date 2012-02-24

Release Date 2013-04-03

Last Version Date 2023-09-13

Entry Detail

PDB ID:

4DWK

Keywords:

HYDROLASE/HYDROLASE INHIBITOR

Title:

Structure of cystein free insulin degrading enzyme with compound bdm41671 ((s)-2-{2-[carboxymethyl-(3-phenyl-propyl)-amino]-acetylamino}-3-(1h-imidazol-4-yl)-propionic acid methyl ester)

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

ESCHERICHIA COLI

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

3.00 Å

R-Value Free:

0.22

R-Value Work:

0.17

R-Value Observed:

0.18

Space Group:

P 65

Download Validation Report

Macromolecular Entities

Structures with similar UniProt ID

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Insulin-degrading enzyme
Gene (Uniprot):IDE
Mutagens:C110L,E111Q,C171S,C178A,C257V,C414L,C573N,C590S,C789S,C812A,C819A,C904S,C966N,C974A
Chain IDs:A, B
Chain Length:990
Number of Molecules:2
Biological Source:Homo sapiens

UniProt ID:P14735 Pfam ID:PF00675, PF05193, PF16187 EC:3.4.24.56

Ligand Molecules

MGK

Primary Citation

Imidazole-derived 2-[N-carbamoylmethyl-alkylamino]acetic acids, substrate-dependent modulators of insulin-degrading enzyme in amyloid-beta hydrolysis.

Charton, J, Gauriot, M, Guo, Q, Hennuyer, N, Marechal, X, Dumont, J, Hamdane, M, Pottiez, V, Landry, V, Sperandio, O, Flipo, M, Buee, L, Staels, B, Leroux, F, Tang, W.J, Deprez, B, Deprez-Poulain, R.Show

Eur.J.Med.Chem. 79 184 193 (2014)

PMID: 24735644 DOI: 10.1016/j.ejmech.2014.04.009

Abstact

Insulin degrading enzyme (IDE) is a highly conserved zinc metalloprotease that is involved in the clearance of various physiologically peptides like amyloid-beta and insulin. This enzyme has been involved in the physiopathology of diabetes and Alzheimer's disease. We describe here a series of small molecules discovered by screening. Co-crystallization of the compounds with IDE revealed a binding both at the permanent exosite and at the discontinuous, conformational catalytic site. Preliminary structure-activity relationships are described. Selective inhibition of amyloid-beta degradation over insulin hydrolysis was possible. Neuroblastoma cells treated with the optimized compound display a dose-dependent increase in amyloid-beta levels.

Legend

Protein

Chemical

Disease

Primary Citation of related structures

Abstact

Feedback Form